NovaBay Pharmaceuticals, Inc. [NYSE:NBY]: Analyst Rating and Earnings
Expert stock traders often make certain they pay attention what leading Wall Street analysts think regarding a potential stock purchase. As it relates to NovaBay Pharmaceuticals, Inc. [NBY] currently, the latest ratings from Wall St. experts that can be seen publicly is related to the fiscal quarter that’s scheduled to end in December. On average, stock market experts give NBY an Outperform rating. Its stock price has been found in the range of 0.23 to 3.74. This is compared to its latest closing price of $0.29.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for NovaBay Pharmaceuticals, Inc. [NBY] is sitting at 2.50. This is compared to 1 month ago, when its average rating was 2.67.
Pay attention to the next-scheduled financial results for this company to be released, which is slated for Tue 6 Aug (In 75 Days).
Fundamental Analysis of NovaBay Pharmaceuticals, Inc. [NBY]
Now let’s turn to look at profitability: with a current Operating Margin for NovaBay Pharmaceuticals, Inc. [NBY] sitting at -62.93 and its Gross Margin at +87.98, this company’s Net Margin is now -40.60%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -208.56, and its Return on Invested Capital has reached -157.50%. Its Return on Equity is -173.42, and its Return on Assets is -67.34. These metrics suggest that this NovaBay Pharmaceuticals, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -0.55. The Enterprise Value to Sales for this firm is now 0.38. NovaBay Pharmaceuticals, Inc. [NBY] has a Price to Book Ratio of 2.67.
Shifting the focus to workforce efficiency, NovaBay Pharmaceuticals, Inc. [NBY] earns $178,686 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.47 and its Total Asset Turnover is 1.29. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.16 and its Current Ratio is 2.24. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
NovaBay Pharmaceuticals, Inc. [NBY] has 18.56M shares outstanding, amounting to a total market cap of $5.53M. Its stock price has been found in the range of 0.23 to 3.74. At its current price, it has moved by -92.04% from its 52-week high, and it has moved 30.23% from its 52-week low.
This stock’s Beta value is currently 1.76, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 33.33. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is NovaBay Pharmaceuticals, Inc. [NBY] a Reliable Buy?
Shares of NovaBay Pharmaceuticals, Inc. [NBY], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.